CA2760159C - Methods of treating bacterial infections using oritavancin - Google Patents

Methods of treating bacterial infections using oritavancin Download PDF

Info

Publication number
CA2760159C
CA2760159C CA2760159A CA2760159A CA2760159C CA 2760159 C CA2760159 C CA 2760159C CA 2760159 A CA2760159 A CA 2760159A CA 2760159 A CA2760159 A CA 2760159A CA 2760159 C CA2760159 C CA 2760159C
Authority
CA
Canada
Prior art keywords
glycopeptide antibiotic
fraction
bound
serum proteins
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2760159A
Other languages
English (en)
French (fr)
Other versions
CA2760159A1 (en
Inventor
Thomas Parr, Jr.
Sylvain Beaulieu
Dario Lehoux
Geoffrey Mckay
Gregory Moeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of CA2760159A1 publication Critical patent/CA2760159A1/en
Application granted granted Critical
Publication of CA2760159C publication Critical patent/CA2760159C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2760159A 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin Active CA2760159C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17345109P 2009-04-28 2009-04-28
US61/173,451 2009-04-28
PCT/US2010/032441 WO2010129233A2 (en) 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin

Publications (2)

Publication Number Publication Date
CA2760159A1 CA2760159A1 (en) 2010-11-11
CA2760159C true CA2760159C (en) 2021-01-12

Family

ID=43050709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2760159A Active CA2760159C (en) 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin

Country Status (11)

Country Link
US (1) US9682061B2 (enExample)
EP (1) EP2424559B1 (enExample)
JP (1) JP2012525391A (enExample)
CN (1) CN102573882A (enExample)
AU (1) AU2010245097B2 (enExample)
BR (1) BRPI1014767A2 (enExample)
CA (1) CA2760159C (enExample)
ES (1) ES2981472T3 (enExample)
PL (1) PL2424559T3 (enExample)
PT (1) PT2424559T (enExample)
WO (1) WO2010129233A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5782615B2 (ja) * 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法
WO2012011450A1 (ja) * 2010-07-20 2012-01-26 シャープ株式会社 コンテンツ配信装置、コンテンツ再生装置、コンテンツ配信システム、コンテンツ配信装置の制御方法、制御プログラム、および、記録媒体
MX385925B (es) 2014-07-17 2025-03-18 The Medicines Co Oritavancina de alta pureza y método para producir la misma.
US10534895B2 (en) 2015-01-20 2020-01-14 Icpd Technologies, Llc System and method for ranking options for medical treatments
CA3014294A1 (en) * 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations
GB2577420B (en) * 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof
KR102189125B1 (ko) * 2018-11-30 2020-12-10 주식회사 리얼타임테크 로그 수집 시스템 및 그 수집 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
DE60136926D1 (de) 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
CA2664444C (en) * 2006-09-25 2015-10-27 Melinta Therapeutics, Inc. Use of oritavancin for prevention and treatment of anthrax
WO2008118784A1 (en) 2007-03-23 2008-10-02 Targanta Therapeutics Corp. Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8518873B2 (en) 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
JP5782615B2 (ja) * 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法

Also Published As

Publication number Publication date
CA2760159A1 (en) 2010-11-11
WO2010129233A9 (en) 2011-02-03
PL2424559T3 (pl) 2024-07-29
US20120035097A1 (en) 2012-02-09
ES2981472T3 (es) 2024-10-09
WO2010129233A2 (en) 2010-11-11
EP2424559A1 (en) 2012-03-07
AU2010245097A9 (en) 2015-08-13
JP2012525391A (ja) 2012-10-22
EP2424559A4 (en) 2012-10-03
CN102573882A (zh) 2012-07-11
AU2010245097B2 (en) 2015-08-13
BRPI1014767A2 (pt) 2016-04-19
US9682061B2 (en) 2017-06-20
AU2010245097A1 (en) 2011-11-10
EP2424559B1 (en) 2024-04-03
PT2424559T (pt) 2024-04-30

Similar Documents

Publication Publication Date Title
US12514899B2 (en) Methods of treatment using single doses of oritavancin
US9682061B2 (en) Methods of treating bacterial infections using oritavancin
WO2011008193A1 (en) Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) Fusidic acid dosing regimens for treatment of bacterial infections
US9089507B2 (en) Use of oritavancin for prevention and treatment of anthrax
JP2006528188A (ja) グリコペプチド抗菌剤と組み合わせたエキノカンジン抗真菌剤の使用
US9775878B2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
AU2004271688B2 (en) A glycopeptide composition with improved antibiotic activity
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
US20160206688A1 (en) Methods for treating bacteremia and osteomyelitis using oritavancin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150408

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260608